Year-End Report

GOODWIN PROCTER LLP for TEVA PHARMACEUTICALS USA INC

Period Year-End 2007 Filed Feb 19, 2008

Official filing
Firm
GOODWIN PROCTER LLP
Client
TEVA PHARMACEUTICALS USA INC
Income
$180,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S.623 ACCESS TO LIFE SAVING MEDICINES ACT; H.R.1038 ACCESS TO LIFE SAVING MEDICINES ACT; S.1505 AFFORDABLE BIOLOGICS FOR CONSUMERS; S.1695 BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2007; H.R. 1956 THE PATIENT PROTECTION AND INNOVATIVE BIOLOGIC MEDICINE ACT; S.1145 PATENT REFORM ACT OF 2007; H.R. 1908 PATENT REFORM ACT OF 2007 (ALL PROVISIONS FOR ALL BILLS)

LobbyistCovered position, as disclosed
ELAINE BLAIS N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1038 (110th), S. 1505 (110th), H.R. 1908 (110th), H.R. 1956 (110th), S. 1695 (110th), S. 623 (110th), S. 1145 (110th)

Pharmacy PHA

S.623 ACCESS TO LIFE SAVING MEDICINES ACT; H.R.1038 ACCESS TO LIFE SAVING MEDICINES ACT; S.1505 AFFORDABLE BIOLOGICS FOR CONSUMERS; S.1695 BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2007; H.R. 1956 THE PATIENT PROTECTION AND INNOVATIVE BIOLOGIC MEDICINE ACT; S.1145 PATENT REFORM ACT OF 2007; H.R. 1908 PATENT REFORM ACT OF 2007 (ALL PROVISIONS FOR ALL BILLS)

LobbyistCovered position, as disclosed
ELAINE BLAIS N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1505 (110th), S. 1695 (110th), H.R. 1908 (110th), H.R. 1956 (110th), H.R. 1038 (110th), S. 1145 (110th), S. 623 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.